<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2604">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 10, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03472482</url>
  </required_header>
  <id_info>
    <org_study_id>S59048</org_study_id>
    <nct_id>NCT03472482</nct_id>
  </id_info>
  <brief_title>Optical Coherence Tomography in Cerebral Amyloidosis</brief_title>
  <official_title>Optical Coherence Tomography in Cerebral Amyloidosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universitaire Ziekenhuizen KU Leuven</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universitaire Ziekenhuizen KU Leuven</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this observational study, the investigators aim to evaluate whether changes in the retinal&#xD;
      and choroidal circulation, as assessed by Optical Coherence Tomography (OCT) and the&#xD;
      quantification of retinal amyloid deposits using auto-fluorescence and hyperspectral retinal&#xD;
      imaging, are correlated with the degree and subtype of dementia and with the presence or&#xD;
      absence of a positive amyloid scan.&#xD;
&#xD;
      For this purpose, patients with established Alzheimer's Disease (AD) and Lewy Body Dementia&#xD;
      (LBD), as well as amyloid positive and amyloid negative Mild Cognitive Impairment (MCI) and&#xD;
      aged matched cognitively intact patients will be included in this cross-sectional study.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Being a direct extension of the central nervous system and the only place in the human body&#xD;
      where the vessels of the central circulation can be visualized directly, the eye provides a&#xD;
      unique window to investigate the central circulatory system. Several studies have&#xD;
      demonstrated that retinal blood vessels show structural and functional alterations in&#xD;
      patients with dementia. These measurements are based on fundus pictures and are hence limited&#xD;
      to the larger retinal vessels.&#xD;
&#xD;
      Until recently, intravenous injection of a contrast agent was necessary to visualize the&#xD;
      retinal microvasculature in detail. While indispensable for the diagnosis of some ocular&#xD;
      vascular diseases (arterial/venous occlusion, neovascularization,â€¦) the invasiveness of&#xD;
      fluorescein angiography (and the risk of an allergic reaction) limits its use as a screening&#xD;
      tool to detect alterations in the microvascular network of the retina and choroid.&#xD;
&#xD;
      Optical coherence tomography (OCT) is a non-invasive diagnostic tool capable of generating&#xD;
      cross-sectional coupes of the retina and choroid. Novel algorithms allow to render a&#xD;
      3-dimensional model of the ocular microcirculation based merely on the motion contrast of the&#xD;
      circulating blood. Since OCT is fast, easy to perform and completely non-invasive, this&#xD;
      technique lends itself for screening purposes.&#xD;
&#xD;
      Auto-fluorescence retinal imaging is an imaging modality that is commonly used in&#xD;
      ophthalmological practice to assess retinal pigment epithelium and photoreceptor function by&#xD;
      quantifying the relative amount of auto-fluorescent lipofuscin. The images can be acquired&#xD;
      using the OCT device but require pupil dilation. Using visible light of 488nm, it is a safe&#xD;
      imaging technique with no short or late term side-effects to the patient. A recent study has&#xD;
      described abnormal auto-fluorescence patterns in patients with cerebral amyloid deposition.&#xD;
&#xD;
      Hyperspectral fundus photography is comparable to regular fundus photography but uses an&#xD;
      image sensor that can acquire images at multiple different wavelengths (unlike the classical&#xD;
      red-green-blue colour sensors that are used in conventional cameras). Apart from a different&#xD;
      image sensor, the device is identical to a regular fundus camera. Recent studies have emerged&#xD;
      that describe a unique hyperspectral signature of aggregated retinal amyloid deposits.&#xD;
&#xD;
      The proposed study aims to investigate whether retinal or choroidal vascular parameters&#xD;
      measured using OCT and the quantification of retinal amyloid deposits using auto-fluorescence&#xD;
      and hyperspectral retinal imaging, could be useful to identify different subpopulations of&#xD;
      cognitive intact, MCI and dementia patients.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">March 25, 2016</start_date>
  <completion_date type="Anticipated">December 31, 2019</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2018</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <target_duration>1 Day</target_duration>
  <primary_outcome>
    <measure>Diagnostic performance of OCT measurements in dementia</measure>
    <time_frame>2 years</time_frame>
    <description>area under the curve (AUC) on receiver operating characteristic curves</description>
  </primary_outcome>
  <number_of_groups>6</number_of_groups>
  <enrollment type="Anticipated">85</enrollment>
  <condition>Alzheimer Disease</condition>
  <condition>Dementia Alzheimers</condition>
  <condition>Dementia</condition>
  <condition>Lewy Body Disease</condition>
  <condition>Dementia, Lewy Body</condition>
  <condition>Mild Cognitive Impairment</condition>
  <arm_group>
    <arm_group_label>Ab+ cognitively intact volunteers</arm_group_label>
    <description>amyloid-positive cognitively intact controls (55-80 years)&#xD;
interventions: non-invasive retinal imaging with Optical Coherence Tomography (OCT), OCT-angiography (OCT-A), Autofluorescence, Fundus Photography, Hyperspectral Imaging</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ab- cognitively intact volunteers</arm_group_label>
    <description>amyloid-negative cognitively intact controls (55-80 years)&#xD;
interventions: non-invasive retinal imaging with Optical Coherence Tomography (OCT), OCT-angiography (OCT-A), Autofluorescence, Fundus Photography, Hyperspectral Imaging</description>
  </arm_group>
  <arm_group>
    <arm_group_label>amyloid-positive MCI patients</arm_group_label>
    <description>amyloid-positive patients with Mild Cognitive Impairment&#xD;
interventions: non-invasive retinal imaging with Optical Coherence Tomography (OCT), OCT-angiography (OCT-A), Autofluorescence, Fundus Photography, Hyperspectral Imaging</description>
  </arm_group>
  <arm_group>
    <arm_group_label>amyloid-negative MCI patients</arm_group_label>
    <description>amyloid-negative patients with Mild Cognitive Impairment&#xD;
interventions: non-invasive retinal imaging with Optical Coherence Tomography (OCT), OCT-angiography (OCT-A), Autofluorescence, Fundus Photography, Hyperspectral Imaging</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AD patients</arm_group_label>
    <description>patients in the dementia stage of Alzheimer's Disease&#xD;
interventions: non-invasive retinal imaging with Optical Coherence Tomography (OCT), OCT-angiography (OCT-A), Autofluorescence, Fundus Photography, Hyperspectral Imaging</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LBD patients</arm_group_label>
    <description>patients with Lewy Body Dementia&#xD;
interventions: non-invasive retinal imaging with Optical Coherence Tomography (OCT), OCT-angiography (OCT-A), Autofluorescence, Fundus Photography, Hyperspectral Imaging</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>non-invasive retinal imaging</intervention_name>
    <arm_group_label>AD patients</arm_group_label>
    <arm_group_label>Ab+ cognitively intact volunteers</arm_group_label>
    <arm_group_label>Ab- cognitively intact volunteers</arm_group_label>
    <arm_group_label>LBD patients</arm_group_label>
    <arm_group_label>amyloid-negative MCI patients</arm_group_label>
    <arm_group_label>amyloid-positive MCI patients</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Cfr. Eligibility Criteria&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Cognitively intact healthy controls will be recruited from an ongoing&#xD;
             community-recruited longitudinal cohort of cognitively intact older adults (55-85&#xD;
             years, S51125) who all have undergone amyloid Positron Emission Tomography (PET) at&#xD;
             the baseline visit in the context of study S51125. Half of the subjects will be&#xD;
             amyloid-positive and half will be amyloid-negative. In the context of study S51125&#xD;
             these subjects receive two-yearly neuropsychological assessment.&#xD;
&#xD;
          -  MCI patients (Petersen et al., 2004 criteria) will be recruited from an ongoing&#xD;
             memory-clinic recruited longitudinal cohort of patients with amnestic mild cognitive&#xD;
             impairment who participate in study S55892. All subjects have undergone an amyloid PET&#xD;
             at the baseline study in the context of study S55892. Half of the subjects will be&#xD;
             amyloid-positive and half will be amyloid negative.&#xD;
&#xD;
          -  Clinically probable AD subjects (National Institute of Neurological Disorders and&#xD;
             Stroke (NINDS) and the Association Internationale pour la Recherche et l'Enseignement&#xD;
             en Neurosciences (AIREN) criteria) will be recruited from the memory clinic University&#xD;
             Hospitals Leuven (MMSE 12-28). Subjects will be recruited only if they are capable of&#xD;
             providing written informed consent.&#xD;
&#xD;
          -  Clinically probable LBD (McKeith et al. criteria, 2005) will be recruited from the&#xD;
             memory clinic University Hospitals Leuven (MMSE 12-28). Subjects will be recruited&#xD;
             only if they are capable of providing written informed consent.&#xD;
&#xD;
          -  Capable and willing to participate&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Personal medical history of retinal neovascularization&#xD;
&#xD;
          -  Unable or unwilling to give consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Evelien Vandewalle, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UZ Leuven/KU Leuven</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Karel Van Keer, MD</last_name>
    <phone>+3216332387</phone>
    <email>karel.vankeer@uzleuven.be</email>
  </overall_contact>
  <location>
    <facility>
      <name>UZ Leuven</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karel Van Keer, MD</last_name>
      <phone>+3216332387</phone>
      <email>karel.vankeer@uzleuven.be</email>
    </contact>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <study_first_submitted>January 19, 2018</study_first_submitted>
  <study_first_submitted_qc>March 20, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 21, 2018</study_first_posted>
  <last_update_submitted>March 20, 2018</last_update_submitted>
  <last_update_submitted_qc>March 20, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 21, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Alzheimer's disease</keyword>
  <keyword>Dementia</keyword>
  <keyword>Lewy body disease</keyword>
  <keyword>Retina</keyword>
  <keyword>Retinal imaging</keyword>
  <keyword>Optical Coherence Tomography</keyword>
  <keyword>Hyperspectral imaging</keyword>
  <keyword>Mild Cognitive Impairment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
    <mesh_term>Dementia</mesh_term>
    <mesh_term>Lewy Body Disease</mesh_term>
    <mesh_term>Amyloidosis</mesh_term>
    <mesh_term>Cognitive Dysfunction</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>April 17, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/82/NCT03472482/Prot_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

